GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (STU:8CC) » Definitions » Cyclically Adjusted PB Ratio

Cocrystal Pharma (STU:8CC) Cyclically Adjusted PB Ratio : 0.05 (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cocrystal Pharma Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Cocrystal Pharma's current share price is €1.86. Cocrystal Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €40.93. Cocrystal Pharma's Cyclically Adjusted PB Ratio for today is 0.05.

The historical rank and industry rank for Cocrystal Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:8CC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.05   Med: 0.25   Max: 1.39
Current: 0.05

During the past years, Cocrystal Pharma's highest Cyclically Adjusted PB Ratio was 1.39. The lowest was 0.05. And the median was 0.25.

STU:8CC's Cyclically Adjusted PB Ratio is ranked better than
92.79% of 652 companies
in the Biotechnology industry
Industry Median: 1.74 vs STU:8CC: 0.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cocrystal Pharma's adjusted book value per share data for the three months ended in Mar. 2024 was €2.042. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €40.93 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cocrystal Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cocrystal Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Cyclically Adjusted PB Ratio Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.62 0.26 0.06 0.04

Cocrystal Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.05 0.04 0.03

Competitive Comparison of Cocrystal Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cocrystal Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Cyclically Adjusted PB Ratio falls into.



Cocrystal Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cocrystal Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.86/40.93
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cocrystal Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cocrystal Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.042/131.7762*131.7762
=2.042

Current CPI (Mar. 2024) = 131.7762.

Cocrystal Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 13.164 100.560 17.251
201409 9.072 100.428 11.904
201412 15.853 99.070 21.087
201503 91.338 99.621 120.820
201506 90.783 100.684 118.818
201509 90.889 100.392 119.303
201512 79.763 99.792 105.327
201603 77.736 100.470 101.958
201606 75.901 101.688 98.359
201609 75.390 101.861 97.531
201612 48.905 101.863 63.267
201703 47.133 102.862 60.382
201706 44.998 103.349 57.375
201709 41.475 104.136 52.484
201712 44.027 104.011 55.780
201803 41.531 105.290 51.979
201806 38.669 106.317 47.929
201809 38.115 106.507 47.158
201812 23.567 105.998 29.298
201903 24.794 107.251 30.464
201906 24.322 108.070 29.657
201909 24.378 108.329 29.654
201912 7.899 108.420 9.601
202003 8.421 108.902 10.190
202006 7.573 108.767 9.175
202009 7.456 109.815 8.947
202012 7.353 109.897 8.817
202103 7.342 111.754 8.657
202106 8.660 114.631 9.955
202109 8.478 115.734 9.653
202112 8.450 117.630 9.466
202203 8.226 121.301 8.936
202206 5.753 125.017 6.064
202209 5.446 125.227 5.731
202212 4.587 125.222 4.827
202303 3.977 127.348 4.115
202306 3.146 128.729 3.220
202309 2.827 129.860 2.869
202312 2.378 129.419 2.421
202403 2.042 131.776 2.042

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cocrystal Pharma  (STU:8CC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cocrystal Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (STU:8CC) Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma (STU:8CC) Headlines

No Headlines